While a BID
dosing schedule is nice, the fundamental cooperative toxicity between interferon, ribavirin and a protease inhibitor must be factored into the mix, Chung added.
BID dosing will not make more patients get treated now, agreed Dr Susannah Naggie, assistant professor of medicine, Infectious Diseases, Duke University. The new regimen will not make a difference for someone who has already decided to wait, she said.